Table 3.

Most common adverse events (≥10% incidence in either treatment group and ≥10% difference between treatment group)

Adverse eventAnastrozole plus gefitinib (n = 43) n (%)Anastrozole plus placebo (n = 50) n (%)
Any gradeCTC Grade 3-4Any gradeCTC Grade 3-4
Diarrhea27 (63)3 (7)9 (18)0
Hot flash9 (21)1 (2)14 (28)0
Fatigue17 (40)2 (5)13 (26)2 (4)
Nausea15 (35)013 (26)0
Rash16 (37)05 (10)0
Pruritus11 (26)05 (10)0
Dry skin6 (14)01 (2)0
Exfoliative rash5 (12)01 (2)0
Acne5 (12)000

Abbreviation: CTC, Common Toxicity Criteria.